Cargando…

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children

BACKGROUND: Fecal Microbiota Transplantation (FMT) is an innovative means of treating recurrent Clostridium difficile infection (rCDI), through restoration of gut floral balance. However, there is a lack of data concerning the efficacy of FMT and its impact on the gut microbiome among pediatric pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fareed, Shaaz, Sarode, Neha, Stewart, Frank J., Malik, Aneeq, Laghaie, Elham, Khizer, Saadia, Yan, Fengxia, Pratte, Zoe, Lewis, Jeffery, Immergluck, Lilly Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984579/
https://www.ncbi.nlm.nih.gov/pubmed/29868248
http://dx.doi.org/10.7717/peerj.4663
_version_ 1783328635343601664
author Fareed, Shaaz
Sarode, Neha
Stewart, Frank J.
Malik, Aneeq
Laghaie, Elham
Khizer, Saadia
Yan, Fengxia
Pratte, Zoe
Lewis, Jeffery
Immergluck, Lilly Cheng
author_facet Fareed, Shaaz
Sarode, Neha
Stewart, Frank J.
Malik, Aneeq
Laghaie, Elham
Khizer, Saadia
Yan, Fengxia
Pratte, Zoe
Lewis, Jeffery
Immergluck, Lilly Cheng
author_sort Fareed, Shaaz
collection PubMed
description BACKGROUND: Fecal Microbiota Transplantation (FMT) is an innovative means of treating recurrent Clostridium difficile infection (rCDI), through restoration of gut floral balance. However, there is a lack of data concerning the efficacy of FMT and its impact on the gut microbiome among pediatric patients. This study analyzes clinical outcomes and microbial community composition among 15 pediatric patients treated for rCDI via FMT. METHODS: This is a prospective, observational, pilot study of 15 children ≤18 years, who presented for rCDI and who met inclusion criteria for FMT at a pediatric hospital and pediatric gastroenterology clinic. Past medical history and demographics were recorded at enrollment and subsequent follow-up. Specimens of the donors’ and the patients’ pre-FMT and post-FMT fecal specimen were collected and used to assess microbiome composition via 16S rRNA gene sequencing. RESULTS: FMT successfully prevented rCDI episodes for minimum of 3 months post-FMT in all patients, with no major adverse effects. Three patients reported continued GI bleeding; however, all three also had underlying Inflammatory Bowel Disease (IBD). Our analyses confirm a significant difference between pre-and post-FMT gut microbiome profiles (Shannon diversity index), whereas no significant difference was observed between post-FMT and donor microbiome profiles. At the phyla level, post-FMT profiles showed significantly increased levels of Bacteroidetes and significantly decreased levels of Proteobacteria. Subjects with underlying IBD showed no difference in their pre-and post-FMT profiles. CONCLUSION: The low rate of recurrence or re-infection by C. difficile, coupled with minimal adverse effects post-FMT, suggests that FMT is a viable therapeutic means to treat pediatric rCDI. Post-FMT microbiomes are different from pre-FMT microbiomes, and similar to those of healthy donors, suggesting successful establishment of a healthier microbiome.
format Online
Article
Text
id pubmed-5984579
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-59845792018-06-04 Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children Fareed, Shaaz Sarode, Neha Stewart, Frank J. Malik, Aneeq Laghaie, Elham Khizer, Saadia Yan, Fengxia Pratte, Zoe Lewis, Jeffery Immergluck, Lilly Cheng PeerJ Microbiology BACKGROUND: Fecal Microbiota Transplantation (FMT) is an innovative means of treating recurrent Clostridium difficile infection (rCDI), through restoration of gut floral balance. However, there is a lack of data concerning the efficacy of FMT and its impact on the gut microbiome among pediatric patients. This study analyzes clinical outcomes and microbial community composition among 15 pediatric patients treated for rCDI via FMT. METHODS: This is a prospective, observational, pilot study of 15 children ≤18 years, who presented for rCDI and who met inclusion criteria for FMT at a pediatric hospital and pediatric gastroenterology clinic. Past medical history and demographics were recorded at enrollment and subsequent follow-up. Specimens of the donors’ and the patients’ pre-FMT and post-FMT fecal specimen were collected and used to assess microbiome composition via 16S rRNA gene sequencing. RESULTS: FMT successfully prevented rCDI episodes for minimum of 3 months post-FMT in all patients, with no major adverse effects. Three patients reported continued GI bleeding; however, all three also had underlying Inflammatory Bowel Disease (IBD). Our analyses confirm a significant difference between pre-and post-FMT gut microbiome profiles (Shannon diversity index), whereas no significant difference was observed between post-FMT and donor microbiome profiles. At the phyla level, post-FMT profiles showed significantly increased levels of Bacteroidetes and significantly decreased levels of Proteobacteria. Subjects with underlying IBD showed no difference in their pre-and post-FMT profiles. CONCLUSION: The low rate of recurrence or re-infection by C. difficile, coupled with minimal adverse effects post-FMT, suggests that FMT is a viable therapeutic means to treat pediatric rCDI. Post-FMT microbiomes are different from pre-FMT microbiomes, and similar to those of healthy donors, suggesting successful establishment of a healthier microbiome. PeerJ Inc. 2018-05-30 /pmc/articles/PMC5984579/ /pubmed/29868248 http://dx.doi.org/10.7717/peerj.4663 Text en ©2018 Fareed et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Microbiology
Fareed, Shaaz
Sarode, Neha
Stewart, Frank J.
Malik, Aneeq
Laghaie, Elham
Khizer, Saadia
Yan, Fengxia
Pratte, Zoe
Lewis, Jeffery
Immergluck, Lilly Cheng
Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title_full Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title_fullStr Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title_full_unstemmed Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title_short Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
title_sort applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984579/
https://www.ncbi.nlm.nih.gov/pubmed/29868248
http://dx.doi.org/10.7717/peerj.4663
work_keys_str_mv AT fareedshaaz applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT sarodeneha applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT stewartfrankj applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT malikaneeq applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT laghaieelham applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT khizersaadia applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT yanfengxia applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT prattezoe applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT lewisjeffery applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren
AT immerglucklillycheng applyingfecalmicrobiotatransplantationfmttotreatrecurrentclostridiumdifficileinfectionsrcdiinchildren